Alkermes plc (Nasdaq: ALKS) reported financial results for the three and nine months ended September 30, 2026, revealing total revenues of $480.1 million for the third quarter. This figure represents an increase compared to the $394.2 million reported in the same period of the previous year. For the nine months ended September 30, 2026, total revenues reached $1,369.1 million, up from $1,091.4 million in 2025.
Revenue was driven by proprietary net sales of $417.3 million, which included sales of VIVITROL, ARISTADA, LYBALVI, and LUMRYZ. Specifically, VIVITROL generated $127.6 million in the quarter, ARISTADA generated $103.9 million, LYBALVI generated $95.9 million, and LUMRYZ generated $89.9 million. Additionally, the company reported manufacturing and royalty revenues of $62.9 million, primarily from VUMERITY and royalties related to XEPLION, INVEGA TRINZA, and TREVICTA.
On the profitability side, the company reported GAAP net income of $16.3 million for the third quarter of 2026, a decrease from $82.8 million in the prior year. Adjusted EBITDA for the quarter was $120.1 million. The company also noted that at the end of the third quarter, approximately 4,100 patients were on LUMRYZ therapy.
Alkermes reiterated its financial expectations for 2026 as set forth in its press release dated July 28, 2026. The company reported cash, cash equivalents, and total investments of $787.6 million as of September 30, 2026, an increase from $691.6 million at the end of the previous quarter.
